NASDAQ:CUTR - Cutera Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $30.67
  • Forecasted Upside: 6.04 %
  • Number of Analysts: 4
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$28.92
▼ -0.02 (-0.07%)
1 month | 3 months | 12 months
Get New Cutera Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for CUTR and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CUTR

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$30.67
▲ +6.04% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Cutera in the last 3 months. The average price target is $30.67, with a high forecast of $42.00 and a low forecast of $24.00. The average price target represents a 6.04% upside from the last price of $28.92.
Buy
The current consensus among 4 investment analysts is to buy stock in Cutera. This rating has held steady since March 2020, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 0 sell ratings
10/30/2019
  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 0 sell ratings
1/28/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 0 sell ratings
4/27/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 0 sell ratings
7/26/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
10/24/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
1/22/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
3/23/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
4/22/2021

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/5/2021Piper SandlerBoost Price TargetOverweight$38.00 ➝ $42.00High
i
2/18/2021Piper SandlerBoost Price TargetOverweight$28.00 ➝ $38.00High
i
11/5/2020Piper SandlerBoost Price TargetOverweight$22.00 ➝ $28.00High
i
9/30/2020Piper SandlerBoost Price TargetOverweight$18.00 ➝ $22.00High
i
9/14/2020StephensBoost Price TargetOverweight$18.00 ➝ $24.00High
i
5/8/2020Maxim GroupReiterated RatingHoldLow
i
5/5/2020Stifel NicolausUpgradeHold ➝ Buy$32.00 ➝ $26.00High
i
4/22/2020Piper SandlerInitiated CoverageOverweight$18.00Low
i
3/23/2020StephensLower Price TargetOverweight$45.00 ➝ $15.00High
i
2/28/2020Maxim GroupReiterated RatingHoldMedium
i
11/8/2019StephensBoost Price TargetOverweight$35.00 ➝ $45.00High
i
8/22/2019SidotiDowngradeBuy ➝ NeutralHigh
i
8/9/2019Maxim GroupReiterated RatingHoldLow
i
2/21/2019StephensLower Price TargetOverweight$40.00 ➝ $25.00High
i
2/11/2019Maxim GroupReiterated RatingHoldMedium
i
1/8/2019Maxim GroupReiterated RatingHoldHigh
i
10/5/2018SidotiSet Price TargetBuy$50.00High
i
Rating by James Sidoti at Sidoti
10/5/2018StephensLower Price TargetUnderperform ➝ Sell$40.00 ➝ $24.94High
i
10/5/2018Stifel NicolausLower Price TargetHold ➝ Hold$45.00 ➝ $29.00High
i
8/8/2018Stifel NicolausLower Price TargetHold ➝ Hold$55.00 ➝ $45.00High
i
4/16/2018Stifel NicolausInitiated CoverageHold ➝ Hold$55.00High
i
3/13/2018StephensInitiated CoverageOverweight$60.00High
i
2/16/2018GabelliReiterated RatingBuyLow
i
11/8/2017Maxim GroupReiterated RatingHoldN/A
i
9/14/2017Maxim GroupDowngradeBuy ➝ HoldLow
i
9/12/2017Roth CapitalBoost Price TargetBuy$41.00 ➝ $47.00High
i
Rating by C. Lewis at Roth Capital
8/9/2017GabelliReiterated RatingBuyHigh
i
8/8/2017Roth CapitalBoost Price TargetBuy$32.00 ➝ $39.00High
i
Rating by C. Lewis at Roth Capital
7/13/2017Maxim GroupReiterated RatingBuy ➝ Buy$27.00 ➝ $33.00Low
i
7/7/2017SidotiReiterated RatingBuy$30.00 ➝ $32.00Medium
i
6/26/2017Roth CapitalInitiated CoverageBuy$32.00High
i
Rating by C. Lewis at Roth Capital
6/3/2017SidotiReiterated RatingBuy$27.00 ➝ $30.00Low
i
4/11/2017SidotiInitiated CoverageBuy ➝ Buy$27.00High
i
1/4/2017Maxim GroupBoost Price TargetBuy$18.00 ➝ $22.00N/A
i
(Data available from 4/22/2016 forward)
Cutera logo
Cutera, Inc., a medical device company, engages in the research, development, manufacture, marketing, and servicing of laser and energy-based aesthetics systems for practitioners worldwide. The company offers truSculpt flex, a bio-electrical muscle stimulation device to treat patients at all fitness levels; truSculpt for the non-surgical body sculpting market; Juliet, a laser for women's intimate health; Secret RF, a fractional radio frequency microneedling device for skin revitalization; and enlighten platform, a laser system that is used for tattoo removal, as well as for the treatment of benign pigmented lesions and acne scars. It also provides excel HR platform, a hair removal solution for various skin types; excel V+, a vascular and benign pigmented lesion treatment platform; and xeo platform, a multi-application platform on which a customer purchases hand piece applications for the removal of unwanted hair, treatment of vascular lesions, and skin revitalization by treating discoloration, fine lines, and laxity. In addition, the company offers GenesisPlus, CoolGlide, and myQ products. Further, it provides pulsed light hand pieces for the treatment of discoloration, hair removal, and vascular treatments; Pearl and Pearl Fractional hand pieces; and post-warranty services through extended service contracts or direct billing, as well as offers Titan hand piece refills, cycle refills, consumable tips, and marketing brochures through the company's website cutera.com. The company markets and sells its products through direct sales force to plastic surgeons, dermatologists, gynecologists, family practitioners, primary care physicians, and other qualified practitioners, as well as for physicians performing aesthetic treatments in non-medical offices. Cutera, Inc. was founded in 1988 and is headquartered in Brisbane, California.
Read More

Today's Range

Now: $28.92
$28.92
$29.40

50 Day Range

MA: $30.71
$26.02
$35.46

52 Week Range

Now: $28.92
$11.02
$38.80

Volume

2,102 shs

Average Volume

228,080 shs

Market Capitalization

$514.28 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.6

Frequently Asked Questions

What sell-side analysts currently cover shares of Cutera?

The following sell-side analysts have issued stock ratings on Cutera in the last twelve months: Maxim Group, Piper Sandler, Stephens, Stifel Nicolaus, and Zacks Investment Research.
View the latest analyst ratings for CUTR.

What is the current price target for Cutera?

3 Wall Street analysts have set twelve-month price targets for Cutera in the last year. Their average twelve-month price target is $30.67, suggesting a possible upside of 6.2%. Piper Sandler has the highest price target set, predicting CUTR will reach $42.00 in the next twelve months. Stephens has the lowest price target set, forecasting a price of $24.00 for Cutera in the next year.
View the latest price targets for CUTR.

What is the current consensus analyst rating for Cutera?

Cutera currently has 1 hold rating and 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe CUTR will outperform the market and that investors should add to their positions of Cutera.
View the latest ratings for CUTR.

What other companies compete with Cutera?

How do I contact Cutera's investor relations team?

Cutera's physical mailing address is 3240 BAYSHORE BOULEVARD, BRISBANE CA, 94005. The medical device company's listed phone number is 415-657-5500 and its investor relations email address is [email protected] The official website for Cutera is www.cutera.com.